Back to top
more

Medtronic (MDT)

(Delayed Data from NYSE)

$92.88 USD

92.88
6,636,881

+1.64 (1.80%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $92.94 +0.06 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (155 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well

by Zacks Equity Research

The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.

Zacks Equity Research

Illumina Banks on New Product Suite Despite Margin Woes

by Zacks Equity Research

The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.

Zacks Equity Research

Abbott (ABT) Launches Pivotal Trial TRILUMINATE in the US

by Zacks Equity Research

Given the lack of an alternative therapy to replace tricuspid regurgitation surgery, Abbott (ABT) should be at an advantage in this space.

Zacks Equity Research

Edwards Lifesciences Hits a 52-Week High on Solid Prospects

by Zacks Equity Research

Edwards Lifesciences (EW) gains from recent impressive developments.

Zacks Equity Research

Here's Why You Should Invest in Amedisys (AMED) Right Now

by Zacks Equity Research

Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.

Zacks Equity Research

Top Ranked Growth Stocks to Buy for September 9th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, September 9th

Zacks Equity Research

Stryker's Mobius Imaging Buyout to Boost Its Spine Division

by Zacks Equity Research

Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.

Zacks Equity Research

Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Investors' optimism continues to be high on solid prospects of Hill-Rom Holdings (HRC).

Zacks Equity Research

Integra LifeSciences' Organic Growth Strong on New Products

by Zacks Equity Research

Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.

Zacks Equity Research

Medtronic Names Next CEO as Omar Ishrak to Step Down in 2020

by Zacks Equity Research

This is indeed a top story as during Omar's tenure, annual revenues of Medtronic (MDT) skyrocket to double-digit growth among a slew of enormous feats that he attains.

Zacks Equity Research

Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System

by Zacks Equity Research

With the launch of this new system, Bruker (BRKR) establishes a performance yardstick for atomic force microscopy in the field of life science research.

Zacks Equity Research

Here's Why You Should Invest in Haemonetics (HAE) Right Now

by Zacks Equity Research

Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.

Zacks Equity Research

Here's Why You Should Hold on to Thermo Fisher (TMO) for Now

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

Zacks Equity Research

Here's Why You Should Invest in Hologic (HOLX) Stock Now

by Zacks Equity Research

Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.

Zacks Equity Research

Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe

by Zacks Equity Research

With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.

Zacks Equity Research

Zacks.com featured highlights include: Target, Medtronic, Microsoft, Teradyne and Darden Restaurants

by Zacks Equity Research

Zacks.com featured highlights include: Target, Medtronic, Microsoft, Teradyne and Darden Restaurants

Zacks Equity Research

Quest Diagnostics' New Acquisitions and Pacts Aid Growth

by Zacks Equity Research

Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.

Zacks Equity Research

Henry Schein Expands SolutionsHub With CueSquared MobilePay

by Zacks Equity Research

The platform is expected to augment Henry Schein's (HSIC) patient revenues, accelerate payments and curb collection costs.

Zacks Equity Research

Zacks.com featured highlights include: Medtronic Public, Symantec, Target, OUTFRONT Media and Atkore International Group

by Zacks Equity Research

Zacks.com featured highlights include: Medtronic Public, Symantec, Target, OUTFRONT Media and Atkore International Group

Zacks Equity Research

Here's Why You Should Hold on to ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors' confidence continues to be high on ResMed's (RMD) prospects.

Sweta Killa headshot

5 Dividend Growth Stocks on Sale

by Sweta Killa

Given the collapse in yields and market uncertainty, the appeal for dividend ETFs has been on rise on investors' drive for juicy yields and consistent income.

Zacks Equity Research

Haemonetics Rides on Strong Plasma and Global Expansion

by Zacks Equity Research

Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).

Zacks Equity Research

Abbott's (ABT) TRACK-TBI Study Reveals Encouraging Results

by Zacks Equity Research

This study outcome should be a crucial step forward for Abbott Laboratories (ABT) in its endeavor to boost TBI diagnosis and treatment.

Zacks Equity Research

5 Solid Stocks Near 52-Week High With More Room to Run

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

Medtronic (MDT) Benefits from Strength Across Business Groups

by Zacks Equity Research

Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.